#esmo_congress_2019

[i-jacoblogan-blog]

renal cell carcinoma: ESMO hears about combination treatments

Pharmaceutical companies are focusing on the development of combination treatments for heavily pre-treated and refractory patient populations.

Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.

[i-jacoblogan-blog]

ESMO: Kisqali shows superior overall survival in breast cancer

Novartis has announced results from the Monaleesa-3 trial at the European Society for Medical Oncology (ESMO) Congress 2019.

Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.

[i-jacoblogan-blog]

Pharmaceutical Technology lists seven promising digital health intervention companies participating in the ESMO Congress 2019 conference.

Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.

[i-jacoblogan-blog]

ESMO Congress 2019: Seven liquid biopsy companies at the conference

Medical Device Network lists seven promising liquid biopsy companies participating in the ESMO Congress 2019 conference being held in September.

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.